Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed later-stage tilt small index

MPS-IH (Hurler Syndrome): later-stage trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

MPS-IH (Hurler Syndrome): 1 US clinical trial tracked, none currently recruiting.

MPS-IH (Hurler Syndrome) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Orchard Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition mps-ih-hurler-syndrome

OPEN 0 | RECR 0% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%MPS-IH (this)0%
Open-enrollment share among volume-matched conditions near MPS-IH (Hurler Syndrome)

MPS-IH (Hurler Syndrome) has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for MPS-IH (Hurler Syndrome) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. MPS-IH (Hurler Syndrome) is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on MPS-IH (Hurler Syndrome) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Active Comparator: Allo-HSCT Genetic
1 trials
Experimental: OTL-203 Genetic
1 trials

US sites by state

Facility locations filed on MPS-IH (Hurler Syndrome) trials. A trial with sites in several states counts in each.

Minnesota 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this MPS-IH (Hurler Syndrome) page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No MPS-IH (Hurler Syndrome) trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Orchard Therapeutics sponsors the most MPS-IH (Hurler Syndrome) trials on record, review their full trial history before evaluating a specific study. See Orchard Therapeutics's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This MPS-IH (Hurler Syndrome) condition card totals 1 registered trials; most-linked intervention Active Comparator: Allo-HSCT; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.